Results showed that 57% of the OCA-treated group reached the primary endpoint of a ≥2-point improvement in NAFLD activity score (NAS) without worsening fibrosis, compared to 21% in the placebo group.
Praluent achieved its primary endpoint by decreasing LDL-C from baseline to Week 24 by 48.2%, compared to a 0.8% increase in the placebo arm.
In the post-hoc analysis of a subgroup of statin-treated women with persistent high TG and type 2 diabetes (n=146), treatment with Vascepa 4g daily lowered TG, other atherogenic lipid markers, and inflammatory markers.
The study found greater reductions in HbA1c among patients taking ertugliflozin 5mg or 15mg with metformin vs. placebo at 26 weeks (0.7% and 0.9% vs. 0.0%; P<0.001).
Study patients who switched to Toujeo were 57% less likely to have hypoglycemia at the 6-month follow-up (OR 0.432, 95% CI: 0.307-0.607; P<0.0001) vs. those who switched to another basal insulin.
After 30 weeks, least squares (LS) mean reductions in HbA1c for the Soliqua 100/33 treatment groups were 1.09%, 1.44% and 2.41%, respectively.
Compared to basal-bolus therapy, Xultophy 100/3.6-treated patients achieved A1c <7% with no hypoglycemia and no weight gain in the last 12 weeks.
Compared to placebo, canagliflozin reduced the risk of the composite primary endpoint (cardiovascular mortality, nonfatal MI, nonfatal stroke) by 14% (HR: 0.86; 95% CI: 0.75-0.97).
The researchers found that the primary outcome of first occurrence of an adjudicated major cardiovascular event occurred in 8.5 and 9.3% of patients in the degludec and glargine groups, respectively.
Results showed that by the end of the 1-year study, there were no significant differences in hemoglobin A1C levels or HRQOL across the three study arms.
Interventions seeking to counteract antipsychotic-induced weight gain and cardiometabolic disturbances have had limited success.